Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 19NETWORK 4NIH 2INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Small Cell Lung Carcinoma 63Leukemia, Myeloid, Acute 14Carcinoma, Non-Small-Cell Lung 14Lung Neoplasms 11Lymphoma, Non-Hodgkin 9Lymphoma, Large B-Cell, Diffuse 9Recurrence 8Neoplasms 8Parkinson Disease 4, Autosomal Dominant Lewy Body 6Lymphoma 5Precursor Cell Lymphoblastic Leukemia-Lymphoma 4Carcinoma, Small Cell 4Ovarian Neoplasms 3Leukemia 3Hodgkin Disease 3Extensive Stage Small Cell Lung Cancer 3Small Cell Lung Cancer Extensive Stage 2SCLC 2Osteosarcoma 2Neoplasm Metastasis 2Lymphoma, B-Cell 2Lymphatic Diseases 2Immunoproliferative Disorders 2Hematologic Diseases 2Glioblastoma 2Ependymoma 2Advanced Solid Tumors 2Widespread Small Cell Lung Cancer 1Unresectable Locally Advanced or Metastatic Solid Tumors 1Squamous Cell Carcinoma of Head and Neck 1

Interventions

Temozolomide 6sonidegib 4Irinotecan 3Topotecan 2LY2940680 2Cyclophosphamide 2ribociclib 1pomalidomide 1palbociclib 1omburtamab I-131 1exatecan 1entrectinib 1dinutuximab 1bempegaldesleukin 1abemaciclib 1TB-403 1Pemetrexed 1ONC206 1Nivolumab 1NVP-LEQ506 1Granulocyte-Macrophage Colony-Stimulating Factor 1Filgrastim 1Fentanyl 1Etoposide 1CLR1404 1Biological Factors 190Y-octreotide, DOTA-Tyr(3)- 11-methyltryptophan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
INDUSTRY × Medulloblastoma × Etoposide × Clear all
NCT02502708 2020-06-04

Study of the IDO Pathway Inhibitor, Indoximod, and Temozolomide for Pediatric Patients With Progressive Primary Malignant Brain Tumors

Lumos Pharma

Phase 1 Completed
81 enrolled
CNSSarcoma

Diffuse Intrinsic Pontine Glioma, Brain Neoplasms, Ependymoma, Glioblastoma, Glioma, Medulloblastoma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡